News & Updates

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.

First-line treatment with tislelizumab + chemotherapy significantly improves overall survival (OS) in patients with advanced or metastatic oesophageal squamous cell carcinoma (ESCC) compared with chemotherapy alone, according to an interim analysis of the RATIONALE-306* trial presented at ESMO GI 2022.

Patients with oesophageal squamous cell carcinoma (ESCC) see better survival and safety outcomes after treatment with neoadjuvant chemoradiation therapy (NCRT) as compared with neoadjuvant chemotherapy (NCT) alone, according to a recent meta-analysis.

Bulevirtide at a dose of 2 mg or 10 mg daily induces biochemical and virological response in patients with chronic hepatitis D virus (HDV) infection, according to results of Study MYR301.

Concentrations of albumin and the ratio between lymphocyte and monocyte counts can predict failure of tacrolimus treatment in patients with ulcerative colitis, reports a recent study.

Treatment with warfarin appears to lead to a higher frequency of upper and major gastrointestinal (GI) bleeding as compared with direct oral anticoagulants (DOACs), a study has found.